Omnicell (OMCL) Set to Announce Quarterly Earnings on Wednesday

Omnicell (NASDAQ:OMCL - Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Wednesday, October 30th. Analysts expect Omnicell to post earnings of $0.41 per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. During the same period in the previous year, the firm posted $0.29 EPS. The company's quarterly revenue was down 7.4% compared to the same quarter last year. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Price Performance

Shares of Omnicell stock traded down $1.17 during trading on Wednesday, hitting $39.93. 362,712 shares of the company were exchanged, compared to its average volume of 517,218. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $45.84. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -86.80, a P/E/G ratio of 45.31 and a beta of 0.83. The firm has a 50 day moving average price of $43.18 and a 200 day moving average price of $34.56.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a research note on Saturday. Barclays raised shares of Omnicell from an "underweight" rating to an "equal weight" rating and upped their price target for the stock from $26.00 to $39.00 in a research report on Friday, August 2nd. Benchmark reissued a "buy" rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Wells Fargo & Company upped their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an "equal weight" rating in a research report on Monday, October 14th. Finally, JPMorgan Chase & Co. upped their target price on shares of Omnicell from $26.00 to $37.00 and gave the company a "neutral" rating in a research note on Friday, August 23rd. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Omnicell currently has an average rating of "Moderate Buy" and a consensus price target of $41.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.